Dermatitis, Atopic Clinical Trials

219 clinical trials for Dermatitis, Atopic across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — RECRUITING · PHASE2
• Effects of Treatments on Atopic Dermatitis — RECRUITING · PHASE2
• A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment - EFC17599 / AQUA — RECRUITING · PHASE3
• A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis. — RECRUITING · PHASE1
• Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. — RECRUITING
• A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis — RECRUITING · PHASE1
• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor — RECRUITING · PHASE3
• A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis — RECRUITING · PHASE3
• A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis — RECRUITING
• Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis — RECRUITING · PHASE3
• Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy — RECRUITING
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) — COMPLETED · PHASE3
• A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo — COMPLETED · PHASE2
• Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) — ACTIVE_NOT_RECRUITING
• A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP) — TERMINATED · PHASE3
• A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) — TERMINATED · PHASE2
• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — COMPLETED · PHASE3
• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE3
• Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) — ACTIVE_NOT_RECRUITING
• Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) — COMPLETED
• Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE1
• Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. — TERMINATED · PHASE2
• A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis — TERMINATED · PHASE2
• A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab — COMPLETED · PHASE2
• Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis — WITHDRAWN
• Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106) — ACTIVE_NOT_RECRUITING
• Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE2
• An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates — COMPLETED · PHASE1
• A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis — COMPLETED · PHASE2
• A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis — NOT_YET_RECRUITING · PHASE3
• A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE4
• An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates — OTHER · PHASE1
• Evaluate the Safety, Tolerability of BAT6026 — ACTIVE_NOT_RECRUITING · PHASE1
• Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids - EFC17561 - SHORE — OTHER · PHASE3
• Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis — NOT_YET_RECRUITING · PHASE4
• Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE3
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE3
• To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE2
• Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) — ACTIVE_NOT_RECRUITING
• A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis. — OTHER · PHASE3
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis — COMPLETED · PHASE1
• A multinational, multicenter, double-blind, placebo-controlled phase 2 study to evaluate efficacy and safety of SAR444656 in adult participants with moderate to severe atopic dermatitis. — OTHER · PHASE2
• A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated — COMPLETED · PHASE2
• A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis — TERMINATED
• Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis — COMPLETED · PHASE4
• Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China — COMPLETED · PHASE4

Refine this search